AstraZeneca’s COPD drug gains third Phase III win
AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In the MIRANDA…
Respiratory
-
-
Sanofi’s bispecific scores in respiratory diseases but fails in eczema
Two of Sanofi’s lunsekimig Phase II trials have met their primary endpoints in respiratory disease, while a study in atopic…
-
AstraZeneca’s novel COPD drug secures double win in Phase III
AstraZeneca’s first-in-class biologic, tozorakimab, has posted a double Phase III win in chronic obstructive pulmonary disease (COPD), which analysts say could position the…
-
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
Upstream Bio’s stock value took a 47% downturn following the debut of topline results from a Phase II trial on…
-
Vitamin D deficiency increases the risk of respiratory tract infection
Respiratory tract infections (RTIs) are widely prevalent and cause significant morbidity and mortality globally. RTIs are broadly divided into upper…
-
Pulmocide stops IPA trial after higher mortality rate in treated patients
Pulmocide has terminated a Phase III trial of its inhaled, respiratory drug after patients in the treatment group saw a…
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the…
-
Mabwell’s mAb leads to 40% reduction in severe COPD exacerbations
Mabwell Bioscience’s anti-ST2 monoclonal antibody (mAb) has led to a 40% reduction in annualised severe exacerbations in patients with chronic…
-
ArkBio commences Phase II study of AK0610 for RSV prevention
Shanghai Ark Biopharmaceutical (ArkBio) has commenced a randomised Phase II study to evaluate the fully human monoclonal antibody, AK0610, for…
-
Tvardi Therapeutics’ stock crashes on Phase II IPF flop
Tvardi Therapeutics’ stock has crashed more than 80% after the company revealed that its idiopathic pulmonary fibrosis (IPF) candidate flunked…
